Regeneron initiates trial for pozelimab + cemdisiran in PNH patients unresponsive to C5 inhibitors
The initiation of this trial by Regeneron represents a significant development in the treatment landscape for PNH, particularly for patients unresponsive to existing therapies. If successful, this combination therapy could disrupt the current market dominated by C5 inhibitors, enhancing Regeneron's competitive positioning.
| Drug | MOA / Company | Stage |
|---|---|---|
| eculizumab | Regeneron | Lead |
| ravulizumab | — | Competing |
Focal Asset
eculizumab
Company
Regeneron
Indication
Hematology / Paroxysmal Nocturnal Hemoglobinuria (PNH)
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The initiation of this trial by Regeneron represents a significant development in the treatment landscape for PNH, particularly for patients unresponsive to existing therapies. If successful, this combination therapy could disrupt the current market dominated by C5 inhibitors, enhancing Regeneron's competitive positioning.
Why it matters
The initiation of this trial by Regeneron represents a significant development in the treatment landscape for PNH, particularly for patients unresponsive to existing therapies. If successful, this combination therapy could disrupt the current market dominated by C5 inhibitors, enhancing Regeneron's competitive positioning.
What changed
Trial Update
Analysis
Regeneron is conducting a study to evaluate the efficacy of pozelimab and cemdisiran in PNH patients inadequately controlled by existing therapies.
The initiation of this trial by Regeneron represents a significant development in the treatment landscape for PNH, particularly for patients unresponsive to existing therapies. If successful, this combination therapy could disrupt the current market dominated by C5 inhibitors, enhancing Regeneron's competitive positioning.
Monitor trial results for efficacy and safety, as well as any announcements regarding patient recruitment and interim findings.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.